Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
US-2024337668-A1 · Oct 10, 2024 · US
Methods and compositions for the diagnosis and prognosis of Alzheimer's disease
US9726678B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9726678-B2 |
| Application number | US-201013263979-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 15, 2010 |
| Priority date | Apr 15, 2009 |
| Publication date | Aug 8, 2017 |
| Grant date | Aug 8, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to methods of diagnosing Alzheimer's disease (AD) in a subject and methods of determining the prognosis in patients with AD. The adhesion molecules P-selectin and L-selectin are described for the first time for use as biomarkers to aid in the diagnosis of AD. The invention further describes the use of one or more of L-selectin, MCP-1, IL-1α, IL-8 and IFN-γ to aid in the prognosis of either accelerated cognitive decline (ACD) or slow cognitive decline (SCD) in patients with AD.
First claim
Opening claim text (preview).
The invention claimed is: 1. An assay comprising the steps of: contacting a sample of a peripheral biological fluid obtained from a patient suffering from Alzheimer's disease with a probe capable of binding specifically to L-selectin, wherein the peripheral biological fluid is serum or plasma; measuring the concentration of L-selectin from the sample specifically bound to the probe; and providing the measured concentration of L-selectin specifically bound to the probe. 2. The assay of claim 1 , wherein the probe capable of binding specifically to L-selectin is an antibody. 3. The assay of claim 2 , wherein the antibody is a monoclonal antibody. 4. The assay of claim 2 , wherein the antibody is a polyclonal antibody. 5. The assay of claim 1 , further comprising the steps of: contacting the sample with a probe capable of binding specifically to a known biomarker of Alzheimer's disease; measuring the concentration of the known biomarker of Alzheimer's disease from the sample specifically bound to the probe; and providing the measured concentration of the known biomarker of Alzheimer's disease specifically bound to the probe. 6. The assay of claim 5 , wherein the known biomarker of Alzheimer's disease is IL-1α. 7. The assay of claim 5 , wherein the known biomarker of Alzheimer's disease is IL-1β. 8. The assay of claim 5 , wherein the known biomarker of Alzheimer's disease is IL-8. 9. The assay of claim 5 , wherein the known biomarker of Alzheimer's disease is IFN-γ. 10. The assay of claim 5 , wherein the known biomarker of Alzheimer's disease is VEGF. 11. The assay of claim 1 , wherein the peripheral biological fluid is serum. 12. The assay of claim 1 , wherein the peripheral biological fluid is plasma. 13. The assay of claim 1 , wherein the patient suffering from Alzheimer's disease has accelerated cognitive decline (ACD). 14. The assay of claim 1 , wherein the patient suffering from Alzheimer's disease has slow cognitive decline (SCD).
Assignees
Inventors
Classifications
- G01N33/6896Primary
Neurological disorders, e.g. Alzheimer's disease · CPC title
Alzheimer · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9726678B2 cover?
- The invention relates to methods of diagnosing Alzheimer's disease (AD) in a subject and methods of determining the prognosis in patients with AD. The adhesion molecules P-selectin and L-selectin are described for the first time for use as biomarkers to aid in the diagnosis of AD. The invention further describes the use of one or more of L-selectin, MCP-1, IL-1α, IL-8 and IFN-γ to aid in the pr…
- Who is the assignee on this patent?
- Corsi Massimiliano, Fitzgerald Stephen Peter, Lamont John V, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/6896. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Aug 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).